APOL1 gene discovery transforms kidney disease treatment in Nigeria and across Africa

tribuneonlineng.com

Discovery of APOL1 kidney-risk gene variants is transforming chronic kidney disease understanding and treatment for people of African ancestry, offering hope, says nephrologist Samuel Ajayi. Ajayi said the variants evolved to protect against sleeping sickness but can damage kidney cells, helping explain why Africans face about four times higher risk. Trials are testing inaxaplin, an oral drug targeting APOL1-related kidney damage. About 25% of Yoruba and 50% of Igbo carry high-risk variants; Nigeria's CKD prevalence is 17.6%. Doctors are screening donors, and Ajayi sees precision medicine expanding.


With a significance score of 4.2, this news ranks in the top 4% of today's 33614 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


APOL1 gene discovery transforms kidney disease treatment in Nigeria and across Africa | News Minimalist